- Home
- AUDC vs MRSN Comparison
AUDC vs MRSN Comparison
Compare AUDC & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- MRSN
- Stock Information
- Founded
- AUDC 1992
- MRSN 2001
- Country
- AUDC Israel
- MRSN United States
- Employees
- AUDC N/A
- MRSN N/A
- Industry
- AUDC Telecommunications Equipment
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- MRSN Health Care
- Exchange
- AUDC Nasdaq
- MRSN Nasdaq
- Market Cap
- AUDC 266.8M
- MRSN 230.0M
- IPO Year
- AUDC 1999
- MRSN 2017
- Fundamental
- Price
- AUDC $8.21
- MRSN $2.21
- Analyst Decision
- AUDC Buy
- MRSN Buy
- Analyst Count
- AUDC 2
- MRSN 6
- Target Price
- AUDC $10.00
- MRSN $6.00
- AVG Volume (30 Days)
- AUDC 99.9K
- MRSN 1.1M
- Earning Date
- AUDC 11-06-2024
- MRSN 11-13-2024
- Dividend Yield
- AUDC 4.38%
- MRSN N/A
- EPS Growth
- AUDC 0.25
- MRSN N/A
- EPS
- AUDC 0.40
- MRSN N/A
- Revenue
- AUDC $244,181,000.00
- MRSN $34,837,000.00
- Revenue This Year
- AUDC N/A
- MRSN N/A
- Revenue Next Year
- AUDC $21.93
- MRSN $7.15
- P/E Ratio
- AUDC $20.45
- MRSN N/A
- Revenue Growth
- AUDC N/A
- MRSN N/A
- 52 Week Low
- AUDC $7.70
- MRSN $1.22
- 52 Week High
- AUDC $14.45
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- AUDC 36.56
- MRSN 51.26
- Support Level
- AUDC $7.70
- MRSN $2.12
- Resistance Level
- AUDC $8.59
- MRSN $2.83
- Average True Range (ATR)
- AUDC 0.34
- MRSN 0.24
- MACD
- AUDC -0.05
- MRSN 0.03
- Stochastic Oscillator
- AUDC 23.72
- MRSN 39.81
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.